Phosphoglycerate mutase 1 in cancer: A promising target for diagnosis and therapy.
PGAM1
cell proliferation
therapeutic target
tumor growth
Journal
IUBMB life
ISSN: 1521-6551
Titre abrégé: IUBMB Life
Pays: England
ID NLM: 100888706
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
15
03
2019
accepted:
22
05
2019
pubmed:
7
6
2019
medline:
16
5
2020
entrez:
7
6
2019
Statut:
ppublish
Résumé
Altered enzymatic machineries are a substantial biochemical characteristic of tumor cell metabolism that switch metabolic profile from oxidative phosphorylation to amplified glycolysis as well as increased lactate production under hypoxia conditions. Reprogrammed metabolic profile is an emerging hallmark of cancer. Overexpression of several glycolytic enzymes and glucose transporters has been reported in 24 different types of cancers that represent approximately 70% of all the cancer cases around the globe. Thus, targeting glycolytic enzymes could serve as tempting avenue for drug design against cancer. Phosphoglycerate mutase 1 (PGAM1) is an important glycolytic enzyme that catalyzes the conversion of 3-phosphoglycerate to 2-phosphoglycerate. Recent investigations have revealed the overexpression of PGAM1 in several human cancers that is linked with tumor growth, survival, and invasion. The aim of this review is to update scientific research network with cancer-specific role of PGAM1 to elucidate its capability as bonafide therapeutic target for cancer therapy. Moreover, we have also summarized the reported genetic and pharmacological inhibitors of PGAM1. This study suggests that further investigations on PGAM1 should focus on the exploration of molecular mechanisms of PGAM1 overexpression in development of cancer, assessment of biosafety profiles of known inhibitors of PGAM1, and utilization of PGAM1 inhibitors in combinatorial therapies. These future studies will surely support the unbiased strategies for the development of novel PGAM1 inhibitors for cancer therapies.
Substances chimiques
Glyceric Acids
0
3-phosphoglycerate
820-11-1
Phosphoglycerate Mutase
EC 5.4.2.11
phosphoglycerate mutase 1, human
EC 5.4.2.11
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1418-1427Informations de copyright
© 2019 International Union of Biochemistry and Molecular Biology.
Références
Moses C, Garcia-Bloj B, Harvey AR, Blancafort P. Hallmarks of cancer: The CRISPR generation. Eur J Cancer. 2018;93:10-18.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30.
Sarfraz I, Rasul A, Hussain G, et al. Malic enzyme 2 as a potential therapeutic drug target for cancer. IUBMB Life. 2018;70:1076-1083.
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144:646-674.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27-47.
Hitosugi T, Zhou L, Fan J, et al. Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation. Nat Commun. 2013;4:1790.
Liberti MV, Locasale JW. The Warburg effect: How does it benefit cancer cells? Trends Biochem Sci. 2016;41:211-218.
Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: Progress and prospects. Mol Cancer. 2013;12:152.
Hitosugi T, Zhou L, Elf S, et al. Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell. 2012;22:585-600.
Wang F, Li RH, Yin GR. Research progress in phosphoglycerate mutase. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2012;24:353-357. Research progress in phosphoglycerate mutase.
Adachi K, Yamasawa S. Quantitative histochemistry of the primate skin IX phosphoglycerate kinase and phosphoglycerate mutase. J Invest Dermatol. 1967;49:22-30.
Tsujino S, Shanske S, Sakoda S, Fenichel G, DiMauro S. The molecular genetic basis of muscle phosphoglycerate mutase (PGAM) deficiency. Am J Hum Genet. 1993;52:472-477.
Ren F, Wu H, Lei Y, et al. Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma. Mol Cancer. 2010;9:81.
Gizak A, Grenda M, Mamczur P, et al. Insulin/IGF1-PI3K-dependent nucleolar localization of a glycolytic enzyme--phosphoglycerate mutase 2, is necessary for proper structure of nucleolus and RNA synthesis. Oncotarget. 2015;6:17237-17250.
Sakoda S, Shanske S, DiMauro S, Schon EA. Isolation of a cDNA encoding the B isozyme of human phosphoglycerate mutase (PGAM) and characterization of the PGAM gene family. J Biol Chem. 1988;263:16899-16905.
Dierick HA, Mercer JF, Glover TW. A phosphoglycerate mutase brain isoform (PGAM 1) pseudogene is localized within the human Menkes disease gene (ATP7 a). Gene. 1997;198:37-41.
Nir I, Herzog P, Wislicki L. The use of medicines in pregnancy. Harefuah. 1977;92:36-41.
Betran E, Wang W, Jin L, Long M. Evolution of the phosphoglycerate mutase processed gene in human and chimpanzee revealing the origin of a new primate gene. Mol Biol Evol. 2002;19:654-663.
Protasova MS, Grigorenko AP, Tyazhelova TV, et al. Whole-genome sequencing identifies a novel ABCB7 gene mutation for X-linked congenital cerebellar ataxia in a large family of Mongolian ancestry. Eur J Hum Genet. 2016;24:550-555.
Jin Q, Pan H, Wang B, et al. The PGAM4 gene in non-obstructive azoospermia. Syst Biol Reprod Med. 2013;59:179-183.
Hong JM, Lee SM. Heme oxygenase-1 protects liver against ischemia/reperfusion injury via phosphoglycerate mutase family member 5-mediated mitochondrial quality control. Life Sci. 2018;200:94-104.
Takeda K. PGAM5: A novel type of protein serine/threonine phosphatase that exists in the mitochondria. J Oral Biosci. 2011;53:122-127.
Shen Y, Zhao S, Wang S, et al. S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma. EBioMedicine, 2019;40:210-223.
Liu SE, Hu JC, Zhang H, et al. Conformation and dynamics of the C-terminal region in human phosphoglycerate mutase 1. Acta Pharmacol Sin. 2017;38:1673-1682.
Oslund RC, Su X, Haugbro M, et al. Bisphosphoglycerate mutase controls serine pathway flux via 3-phosphoglycerate. Nat Chem Biol. 2017;13:1081-1087.
Zhang D, Jin N, Sun W, et al. Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity. Oncogene. 2017;36:2900-2909.
Olson MF, Sahai E. The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis. 2009;26:273-287.
Li C, Shu F, Lei B, Lv D, Zhang S, Mao X. Expression of PGAM1 in renal clear cell carcinoma and its clinical significance. Int J Clin Exp Pathol. 2015;8:9410-9415.
Liu ZG, Ding J, Du C, et al. Phosphoglycerate mutase 1 is highly expressed in C6 glioma cells and human astrocytoma. Oncol Lett. 2018;15:8935-8940.
Zhang D, Wu H, Zhang X, et al. Phosphoglycerate mutase 1 predicts the poor prognosis of Oral squamous cell carcinoma and is associated with cell migration. J Cancer. 2017;8:1943-1951.
Ishikawa M, Inoue T, Shirai T, et al. Simultaneous expression of cancer stem cell-like properties and cancer-associated fibroblast-like properties in a primary culture of breast cancer cells. Cancers (Basel). 2014;6:1570-1578.
Huang LJ, Chen SX, Luo WJ, Jiang HH, Zhang PF, Yi H. Proteomic analysis of secreted proteins of non-small cell lung cancer. Ai Zheng. 2006;25:1361-1367.
Liu X, Tan X, Liu P, Wu Y, Qian S, Zhang X. Phosphoglycerate mutase 1 (PGAM1) promotes pancreatic ductal adenocarcinoma (PDAC) metastasis by acting as a novel downstream target of the PI3K/Akt/mTOR pathway. Oncol Res. 2018;26:1123-1131.
Wen YA, Zhou BW, Lv DJ, et al. Phosphoglycerate mutase 1 knockdown inhibits prostate cancer cell growth, migration, and invasion. Asian J Androl. 2018;20:178-183.
Liu L, Wang S, Zhang Q, Ding Y. Identification of potential genes/proteins regulated by Tiam1 in colorectal cancer by microarray analysis and proteome analysis. Cell Biol Int. 2008;32:1215-1222.
Peng XC, Gong FM, Chen Y, et al. Proteomics identification of PGAM1 as a potential therapeutic target for urothelial bladder cancer. J Proteomics. 2016;132:85-92.
Sun Q, Li S, Wang Y, et al. Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis. Cell Death Differ. 2018;25:1160-1173.
Wang P, Jiang L, Cao Y, Ye D, Zhou L. The design and synthesis of N-Xanthone Benzenesulfonamides as novel phosphoglycerate mutase 1 (PGAM1) inhibitors. Molecules. 2018;23:1-15.
Singh D, Arora R, Kaur P, Singh B, Mannan R, Arora S. Overexpression of hypoxia-inducible factor and metabolic pathways: Possible targets of cancer. Cell Biosci. 2017;7:62.
Zhang X, Zhao H, Li Y, et al. The role of YAP/TAZ activity in cancer metabolic reprogramming. Mol Cancer. 2018;17:134.
Gao H, Yu B, Yan Y, et al. Correlation of expression levels of ANXA2, PGAM1, and CALR with glioma grade and prognosis. J Neurosurg. 2013;118:846-853.
Miao P, Sheng S, Sun X, Liu J, Huang G. Lactate dehydrogenase a in cancer: A promising target for diagnosis and therapy. IUBMB Life. 2013;65:904-910.
Liu X, Weng Y, Liu P, et al. Identification of PGAM1 as a putative therapeutic target for pancreatic ductal adenocarcinoma metastasis using quantitative proteomics. Onco Targets Ther. 2018;11:3345-3357.
Xu Z, Gong J, Wang C, et al. The diagnostic value and functional roles of phosphoglycerate mutase 1 in glioma. Oncol Rep. 2016;36:2236-2244.
Evans MJ, Morris GM, Wu J, Olson AJ, Sorensen EJ, Cravatt BF. Mechanistic and structural requirements for active site labeling of phosphoglycerate mutase by spiroepoxides. Mol Biosyst. 2007;3:495-506.
Evans MJ, Saghatelian A, Sorensen EJ, Cravatt BF. Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat Biotechnol. 2005;23:1303-1307.
Wang P, Jiang L, Cao Y, et al. Xanthone derivatives as phosphoglycerate mutase 1 inhibitors: Design, synthesis, and biological evaluation. Bioorg Med Chem. 2018;26:1961-1970.
Huang K, Jiang L, Liang R, et al. Synthesis and biological evaluation of anthraquinone derivatives as allosteric phosphoglycerate mutase 1 inhibitors for cancer treatment. Eur J Med Chem. 2019;168:45-57.
Li X, Tang S, Wang QQ, et al. Identification of Epigallocatechin-3- Gallate as an inhibitor of phosphoglycerate mutase 1. Front Pharmacol. 2017;8:325.